Trattamento endovascolare delle steno-occlusioni femoro-poplitee mediante aterotomo direzionale SilverHawk: risultati immediati e follow-up a 12 mesi

Regine, R.; Catalano, Orlando; Siero, Michele De; Costanzo, Giuseppe; Ragozzino, Alfonso

doi:10.1007/s11547-010-0570-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ergebnisse1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2011

2017

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bezüglich der postinterventionellen DAP zeigt sich auch hier tendenziell eine längere Therapiedauer im Bereich der Unterschenkelgefäße. In den wenigen klinischen Studien wurde ähnlich wie bei der Therapie mit medikamentenbeschichteten Ballons oder Stents eine DAP für 4 bis 12 Wochen durchgeführt [38][39][40][41][42].…”

Section: Ergebnisseunclassified

Praxis der Thrombozyten-Aggregationshemmung nach Katheterintervention der Becken- / Beinarterien in Deutschland

Baumhäkel¹,

Kindermann²

2016

Dtsch med Wochenschr

View full text Add to dashboard Cite

show abstract

Section: Ergebnisseunclassified

Praxis der Thrombozyten-Aggregationshemmung nach Katheterintervention der Becken- / Beinarterien in Deutschland

Baumhäkel¹,

Kindermann²

2016

Dtsch med Wochenschr

View full text Add to dashboard Cite

show abstract

12‐month primary patency rates of contemporary endovascular device therapy for femoro‐popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty

Marmagkiolis

Hakeem

Choksi

et al. 2014

Cathet Cardio Intervent

View full text Add to dashboard Cite

The most frequently used endovascular devices yielded various 12-month primary patency rates ranging from 51% to 85%. The increased variation in inclusion criteria, length, and complexity of lesions between studies does not allow direct comparison between them. Larger randomized trials in specific patient populations comparing those modalities is needed before we can make safe recommendation of the superiority of one device over the other.

show abstract

IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease

Peterson

Hasenbank

Silvestro

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Trattamento endovascolare delle steno-occlusioni femoro-poplitee mediante aterotomo direzionale SilverHawk: risultati immediati e follow-up a 12 mesi

Abstract: The SilverHawk directional atherectomy device proved to be an effective and safe tool in all our patients treated for femoropopliteal stenosis/occlusion, with a significant improvement in both imaging findings and clinical signs and symptoms.

Cited by 4 publications

References 20 publications

Praxis der Thrombozyten-Aggregationshemmung nach Katheterintervention der Becken- / Beinarterien in Deutschland

Praxis der Thrombozyten-Aggregationshemmung nach Katheterintervention der Becken- / Beinarterien in Deutschland

12‐month primary patency rates of contemporary endovascular device therapy for femoro‐popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty

IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease

Contact Info

Product

Resources

About